Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-Lewis Y anti-idiotypic antibodies and uses thereof

An anti-idiotypic antibody and anti-idiotype technology, applied in the field of molecular biology, can solve the problem of undetectable HAHA immune response

Inactive Publication Date: 2006-11-22
WYETH LLC +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, HAHA immune responses cannot be detected in the absence of clinical symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-Lewis Y anti-idiotypic antibodies and uses thereof
  • Anti-Lewis Y anti-idiotypic antibodies and uses thereof
  • Anti-Lewis Y anti-idiotypic antibodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] cell culture

[0038] All analytical grade reagents were purchased from Sigma Chemical Co. (St Louis, MO, USA), unless otherwise noted.

[0039] The SP2 / 0-Ag14 plasmacytoma cell line was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). SP2 / 0 and selected hybridoma clones were cultured in standard RPMI-1640 medium; it was a medium containing 10% heat-inactivated fetal calf serum (FCS, TRACE Biosciences Pty Ltd, Sydney, Australia), 100 μg / ml streptomycin , 100 U / ml penicillin (Gibco) and 4 mM L-glutamine in RPMI-1640 medium (Gibco Invitrogen Corp., Mt Waverley, Victoria, Australia). The initial few passages of fusion products were cultured with RPMI-1640 containing 20% ​​FCS, penicillin, streptomycin and L-glutamine as described above. Hybridomas were selected using HAT medium; it was medium supplement containing 20% ​​FCS, HAT (hypoxanthine, aminopterin, thymine), OPI (oxaloacetate, pyruvate, insulin) (Sigma ), penicillin, streptomycin, L...

Embodiment 2

[0041] Antibodies for Immunization and Screening

[0042]Humanized anti-Lewis Y IgG1 antibody hu3S193 (lot: D01097, 10 mg / ml PBS), murine 3S193 (mu3S193), control isotype-matched humanized mAb huA33 (lot: 5GMA33 10 mg / ml) and an irrelevant isotype-matched The mouse:human chimeric IgG1 antibody was provided by Biological Production Facility, Ludwig Institute for Cancer Research, Melbourne, Australia. Purified human IgG was purchased from Sigma Chemical Co. F(ab)' was prepared by digestion with immobilized pepsin according to the manufacturer's instructions (Pierce, Rockford, IL, USA). 2 Fragments, undigested hu3S193 and Fc-containing fragments were purified by passing through a 1 ml protein-A column (Pharmacia Biotech, Uppsala, Sweden). Purified fragments were concentrated to 1 mg / ml in Millipore centrifugal filters (Biomax 10k membrane, Millipore, Sydney, Australia).

Embodiment 3

[0044] Immunization program

[0045] Six to eight week old female BALB / c mice purchased from the Breeding Facility, Walter and Eliza Hall Institute, Melbourne, Australia were fed ad libitum food and water. All procedures performed on animals used in this study were approved by the Animal Ethics Committee of Austin and Repatriation Medical Centre. Pre-immune venous blood samples (200 μl) were collected from each animal and clotted for 1 hour at room temperature and overnight at 4°C. The resulting serum (about 100 μl / mouse) was collected and stored at -20°C.

[0046] The immunization step was performed with six mice. On day 0, BALB / c mice were immunized by intraperitoneal injection of 200 μl containing 40 μg of purified hu3S193:complete Freund's adjuvant (1:1, v:v). Mice received booster injections on days 14 and 28 in incomplete Freund's adjuvant containing 40 μg hu3S193. On day 35, post-immunization blood samples were collected from the tail vein, and serum titers of mouse...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention provides anti-idiotype antibodies specific for Anti-Lewis Y monoclonal antibodies. The present invention also directed against an ELISA screening method of mAbs produced by hybridoma clones for specific binding to the variable regions of hu3S193 and the ability of the anti-idiotypic mAB to inhibit hu3S193 binding to Lewis Y antigen. Additionally, the present invention provides a hybridoma capable of producing an anti-idiotype antibody specific for anti-Lewis Y monoclonal antibody. A further aspect of the invention is to provide a hybridoma, which is specific for anti-Lewis Y monoclonal antibody selected from the group consisting of LMH-1, LMH-2, LMH-3, or LMH-4. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses using the antibody of the invention.

Description

field of invention [0001] The present invention relates to the field of molecular biology, more particularly to antibodies. Background of the invention [0002] The advent of monoclonal antibody (mAb) technology 25 years ago provided a wealth of useful research reagents and created opportunities to use antibodies as approved reagents in cancer therapy, autoimmune disorders, transplant rejection, antiviral prophylaxis, and as antithrombotic agents ( Glennie and Johnson 2000). Using molecular engineering to convert murine mAbs into chimeric mAbs (mouse V-region, human C-region) and humanized reagents, where only the murine mAb complementarity-determining regions (CDRs) are critical for the clinical success of mAb therapy . Engineered mAbs have significantly reduced or lost immunogenicity, increased serum half-life and the human Fc portion of the mAb has increased ability to recruit complement and cytotoxic cellular immune effectors (Clark 2000). Studying the biodistribution...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/42C07K16/28
CPCC07K16/2896C07K16/4266
Inventor Z·刘A·M·斯科特F·E·史密斯
Owner WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com